157 related articles for article (PubMed ID: 17328524)
1. Synthesis and biological evaluation of [18F]bicalutamide, 4-[76Br]bromobicalutamide, and 4-[76Br]bromo-thiobicalutamide as non-steroidal androgens for prostate cancer imaging.
Parent EE; Dence CS; Jenks C; Sharp TL; Welch MJ; Katzenellenbogen JA
J Med Chem; 2007 Mar; 50(5):1028-40. PubMed ID: 17328524
[TBL] [Abstract][Full Text] [Related]
2. Chiral nonsteroidal affinity ligands for the androgen receptor. 1. Bicalutamide analogues bearing electrophilic groups in the B aromatic ring.
Kirkovsky L; Mukherjee A; Yin D; Dalton JT; Miller DD
J Med Chem; 2000 Feb; 43(4):581-90. PubMed ID: 10691684
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological evaluation of a nonsteroidal bromine-76-labeled androgen receptor ligand 3-[76Br]bromo-hydroxyflutamide.
Parent EE; Jenks C; Sharp T; Welch MJ; Katzenellenbogen JA
Nucl Med Biol; 2006 Aug; 33(6):705-13. PubMed ID: 16934689
[TBL] [Abstract][Full Text] [Related]
4. Chemical Degradation of Androgen Receptor (AR) Using Bicalutamide Analog-Thalidomide PROTACs.
Kim GY; Song CW; Yang YS; Lee NR; Yoo HS; Son SH; Lee SJ; Park JS; Lee JK; Inn KS; Kim NJ
Molecules; 2021 Apr; 26(9):. PubMed ID: 33926033
[TBL] [Abstract][Full Text] [Related]
5. Biological properties of androgen receptor pure antagonist for treatment of castration-resistant prostate cancer: optimization from lead compound to CH5137291.
Kawata H; Arai S; Nakagawa T; Ishikura N; Nishimoto A; Yoshino H; Shiraishi T; Tachibana K; Nakamura R; Sato H
Prostate; 2011 Sep; 71(12):1344-56. PubMed ID: 21308717
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and preliminary investigations into novel 1,2,3-triazole-derived androgen receptor antagonists inspired by bicalutamide.
Altimari JM; Niranjan B; Risbridger GP; Schweiker SS; Lohning AE; Henderson LC
Bioorg Med Chem Lett; 2014 Nov; 24(21):4948-53. PubMed ID: 25301770
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of a fluorine-18-labeled nonsteroidal androgen receptor antagonist, N-(3-[18F]fluoro-4-nitronaphthyl)-cis-5-norbornene-endo-2,3-dicarboxylic imide.
Parent EE; Dence CS; Sharp TL; Welch MJ; Katzenellenbogen JA
Nucl Med Biol; 2006 Jul; 33(5):615-24. PubMed ID: 16843836
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and Biological Evaluation of Bicalutamide Analogues for the Potential Treatment of Prostate Cancer.
Kandil SB; McGuigan C; Westwell AD
Molecules; 2020 Dec; 26(1):. PubMed ID: 33374450
[TBL] [Abstract][Full Text] [Related]
9. Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient.
Yoshida T; Kinoshita H; Segawa T; Nakamura E; Inoue T; Shimizu Y; Kamoto T; Ogawa O
Cancer Res; 2005 Nov; 65(21):9611-6. PubMed ID: 16266977
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of novel bicalutamide and enzalutamide derivatives as antiproliferative agents for the treatment of prostate cancer.
Bassetto M; Ferla S; Pertusati F; Kandil S; Westwell AD; Brancale A; McGuigan C
Eur J Med Chem; 2016 Aug; 118():230-43. PubMed ID: 27131065
[TBL] [Abstract][Full Text] [Related]
11. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
[TBL] [Abstract][Full Text] [Related]
12. Interaction mechanism exploration of R-bicalutamide/S-1 with WT/W741L AR using molecular dynamics simulations.
Liu H; An X; Li S; Wang Y; Li J; Liu H
Mol Biosyst; 2015 Dec; 11(12):3347-54. PubMed ID: 26442831
[TBL] [Abstract][Full Text] [Related]
13. Toward development of targeted nonsteroidal antiandrogen-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-gadolinium complex for prostate cancer diagnostics.
Marom H; Miller K; Bechor-Bar Y; Tsarfaty G; Satchi-Fainaro R; Gozin M
J Med Chem; 2010 Sep; 53(17):6316-25. PubMed ID: 20715870
[TBL] [Abstract][Full Text] [Related]
14. Discovery of deshydroxy bicalutamide derivatives as androgen receptor antagonists.
Kandil S; Lee KY; Davies L; Rizzo SA; Dart DA; Westwell AD
Eur J Med Chem; 2019 Apr; 167():49-60. PubMed ID: 30743097
[TBL] [Abstract][Full Text] [Related]
15. Development of 5N-Bicalutamide, a High-Affinity Reversible Covalent Antiandrogen.
de Jesus Cortez F; Nguyen P; Truillet C; Tian B; Kuchenbecker KM; Evans MJ; Webb P; Jacobson MP; Fletterick RJ; England PM
ACS Chem Biol; 2017 Dec; 12(12):2934-2939. PubMed ID: 28981251
[TBL] [Abstract][Full Text] [Related]
16. Affinity labeling of the androgen receptor with nonsteroidal chemoaffinity ligands.
Mukherjee A; Kirkovsky LI; Kimura Y; Marvel MM; Miller DD; Dalton JT
Biochem Pharmacol; 1999 Oct; 58(8):1259-67. PubMed ID: 10487527
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, biological evaluation and X-ray analysis of bicalutamide sulfoxide analogues for the potential treatment of prostate cancer.
Kandil SB; Kariuki BM; McGuigan C; Westwell AD
Bioorg Med Chem Lett; 2021 Mar; 36():127817. PubMed ID: 33513386
[TBL] [Abstract][Full Text] [Related]
18. Novel nonsteroidal ligands with high binding affinity and potent functional activity for the androgen receptor.
He Y; Yin D; Perera M; Kirkovsky L; Stourman N; Li W; Dalton JT; Miller DD
Eur J Med Chem; 2002 Aug; 37(8):619-34. PubMed ID: 12161060
[TBL] [Abstract][Full Text] [Related]
19. 2-(2,2,2-Trifluoroethyl)-5,6-dichlorobenzimidazole derivatives as potent androgen receptor antagonists.
Ng RA; Guan J; Alford VC; Lanter JC; Allan GF; Sbriscia T; Lundeen SG; Sui Z
Bioorg Med Chem Lett; 2007 Feb; 17(4):955-8. PubMed ID: 17134895
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanism of R-bicalutamide switching from androgen receptor antagonist to agonist induced by amino acid mutations using molecular dynamics simulations and free energy calculation.
Liu H; Han R; Li J; Liu H; Zheng L
J Comput Aided Mol Des; 2016 Dec; 30(12):1189-1200. PubMed ID: 27848066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]